Conditions we commonly review

Persistent musculoskeletal, post-surgical, or inflammatory pain lasting more than three months. Cannabinoids — typically THC, CBD, or a balanced ratio — may be considered when conventional analgesics, NSAIDs, or low-dose opioids have failed or caused intolerable side effects. The doctor will want a current pain diary, prior treatment history, and your physiotherapy or specialist notes if you have them.

Chronic sleep-onset or sleep-maintenance insomnia where cognitive behavioural therapy for insomnia (CBT-I), sleep hygiene measures, and short-course conventional sleep medication have been tried without sustained benefit. Cannabinoid options — typically indica-leaning THC strains or balanced THC:CBD oils — may be discussed. The doctor will ask about caffeine, screen-time, shift work, and any underlying anxiety driving the wakefulness.

Generalised anxiety disorder, social anxiety, or PTSD-related anxiety where SSRIs, SNRIs, or psychotherapy have been trialled. CBD-dominant or low-THC formulations are most commonly discussed. Cannabinoids are not first-line and are considered alongside, not instead of, ongoing psychological care. The doctor will need your current treatment plan and any history of psychosis or bipolar disorder, which can change suitability.

Burning, electric, or tingling pain from peripheral neuropathy — diabetic, post-herpetic, post-surgical, or chemotherapy-induced. Cannabinoids have a clinical evidence base for neuropathic pain specifically. Balanced THC:CBD products are commonly considered when gabapentin, pregabalin, or duloxetine have not delivered adequate relief. Bring HbA1c results if diabetes is a factor, and a list of current neuropathic agents.

Pelvic pain, dysmenorrhoea, and inflammatory symptoms of confirmed or strongly suspected endometriosis. Cannabinoids may be discussed alongside — not instead of — gynaecological care, hormonal therapy, or surgical management. The doctor will ask about your specialist diagnosis, current hormonal regimen, and pain pattern across the cycle. A balanced or CBD-leaning formulation is common.

MS-related spasticity, neuropathic pain, and sleep disturbance. Cannabinoid combinations — particularly THC:CBD oromucosal sprays, where available — have established use for MS spasticity. The doctor will want your neurologist’s most recent letter, MRI summary if available, your current disease-modifying therapy, and your spasticity-rating self-assessment.

Treatment-resistant epilepsy where multiple anti-seizure medications have failed. High-CBD pharmaceutical-grade products have a strong evidence base for specific syndromes including Dravet and Lennox-Gastaut. This pathway is rigorously gated — the doctor will require recent neurology correspondence, EEG results, and full medication history. Paediatric cases are accepted only with the treating paediatric neurologist in the loop.

Pain, chemotherapy-induced nausea, appetite loss, and palliative symptoms in active or post-treatment oncology patients. Cannabinoids are considered as adjunctive symptom management — never as cancer therapy. The doctor will require your oncology team’s current treatment plan and confirm coordination with palliative care where applicable. Both THC and CBD formulations may be appropriate depending on symptom mix.